Adagio Medical Holdings, Inc (ADGM) Key Metrics
ADGM valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.7M
- Enterprise value
- $23.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 205.8
- Price / book
- 2.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.01
ADGM key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsADGM valuation Price multiples at each fiscal year-end price.
ADGM returns How much profit the business earns on the capital it uses.
ADGM per-share figures Results divided by the shares outstanding at year-end.
ADGM financial health Debt, liquidity and how easily interest is covered.
ADGM efficiency & capital use Working capital cycle and where the cash goes.
ADGM valuation history
ADGM returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ADGM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ADGM cash returned to shareholders
ADGM price vs earnings per share
ADGM key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $17.2M | $16.0M | — | — | — | — |
| Enterprise value | $21.9M | $11.6M | — | — | — | — |
| Price / sales | — | 59.3 | — | — | — | — |
| Price / book | 1.4 | 0.8 | — | — | — | — |
| EV / sales | — | 43.3 | — | — | — | — |
| Earnings yield | −145.5% | −336.9% | — | — | — | — |
| Free cash flow yield | −112.5% | −194.9% | — | — | — | — |
| Share price at fiscal year-end | $1.04 | $1.05 | — | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.02 | $0.02 | $0.01 | $0.01 | $0.00 |
| Earnings per share | −$1.51 | −$3.54 | −$2.85 | −$1.23 | −$1.04 | −$0.00 |
| Operating cash flow per share | −$1.15 | −$1.94 | −$0.05 | −$1.17 | −$1.01 | — |
| Free cash flow per share | −$1.17 | −$2.05 | −$0.05 | −$1.19 | −$1.07 | — |
| Cash per share | $1.03 | $1.35 | $0.10 | $0.29 | $0.98 | — |
| Book value per share | $0.75 | $1.31 | −$9.86 | −$5.00 | −$3.78 | −$0.00 |
| Tangible book value per share | −$0.51 | −$0.07 | −$9.86 | −$5.00 | −$3.78 | −$0.00 |
| Capex per share | $0.02 | $0.11 | $0.00 | $0.03 | $0.07 | — |
| Debt per share | $1.31 | $1.07 | $2.87 | $0.51 | — | $0.00 |
| Shares outstanding | 16.6M | 15.2M | 13.4M | 19.2M | 19.2M | 19.2M |
| Change in shares outstanding | +9.1% | +13.5% | −30.2% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −155.3% | — | — | — | — | — |
| Return on invested capital (ROIC) | −105.9% | — | — | — | — | — |
| Return on assets (ROA) | −54.7% | −194.5% | −491.5% | −157.1% | −185.6% | −31.9% |
| Return on tangible assets | −112.4% | −195.4% | −558.9% | −272.2% | −93.0% | −31.9% |
| Free cash flow margin | — | — | −242.0% | — | — | — |
| Financial health | ||||||
| Total debt | $21.8M | $16.3M | $38.4M | $9.8M | — | $11,216 |
| Cash & short-term investments | $17.1M | $20.6M | $1.4M | $5.5M | $18.9M | — |
| Net debt | $4.7M | −$4.3M | $37.0M | $4.2M | −$18.9M | $11,216 |
| Debt / equity | 1.75 | 0.82 | — | — | — | — |
| Debt / assets | 0.50 | 0.34 | 5.63 | 1.13 | — | 0.26 |
| Current ratio | 2.44 | 3.27 | 0.11 | 0.52 | 7.62 | 0.03 |
| Quick ratio | 2.24 | 2.93 | 0.04 | 0.49 | 7.49 | 0.03 |
| Interest coverage | -7.5 | -56.7 | -16.8 | -174.5 | — | — |
| Working capital | $11.8M | $17.6M | −$42.0M | −$6.2M | $17.1M | −$54,244 |
| Invested capital | $17.1M | $15.6M | −$95.0M | −$91.6M | −$91.5M | −$2,323 |
| Tangible asset value | −$8.5M | −$1.0M | −$132.0M | −$95.9M | −$72.6M | −$13,539 |
| Net current asset value | −$10.8M | −$3.2M | −$133.7M | −$97.8M | −$74.3M | −$54,244 |
| Graham net-net per share | −$0.78 | −$0.44 | −$10.14 | −$5.41 | −$3.91 | −$0.00 |
| Capital allocation | ||||||
| Share buybacks (net) | — | — | $115.1M | — | — | — |
| Capex / revenue | — | 612.6% | 0.0% | 260.3% | 471.1% | — |
| Capex / depreciation | 0.39 | 1.19 | 0.00 | 0.99 | 3.79 | — |
| Stock-based compensation / revenue | — | 238.7% | 147.3% | 193.1% | 125.6% | — |
| R&D / revenue | — | 1,722.7% | 5,133.0% | 9,447.1% | 5,687.0% | — |
| SG&A / revenue | — | — | 3,845.7% | 533.9% | 2,449.7% | — |
| Efficiency | ||||||
| Days sales outstanding | — | 71.9 | -3,963.0 | -6,327.2 | 44.6 | — |
| Days of inventory on hand | 1,130.8 | 554.8 | 515.5 | 146.2 | 105.3 | — |
| Days payables outstanding | 1,046.4 | 628.4 | 676.5 | 331.4 | 95.0 | — |
| Cash conversion cycle (days) | — | -1.8 | -4,124.0 | -6,512.4 | 54.9 | — |
| Receivables turnover | 0.00 | 5.08 | — | — | 8.18 | — |
| Payables turnover | 0.35 | 0.58 | 0.54 | 1.10 | 3.84 | — |
| Inventory turnover | 0.32 | 0.66 | 0.71 | 2.50 | 3.47 | — |
| Asset turnover | 0.00 | 0.01 | 0.04 | 0.01 | 0.03 | 0.00 |
| Average receivables | $17,500 | $53,000 | −$3.3M | −$3.3M | $33,000 | — |
| Average payables | $2.0M | $3.3M | $2.4M | $794,500 | $301,500 | $25,000 |
| Average inventory | $2.1M | $2.9M | $1.8M | $350,500 | $334,000 | — |
| Intangibles / total assets | 48.4% | 43.2% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ADGM's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ADGM valuation and financial ratios
Adagio Medical earned a return on equity of −155.3% and a return on invested capital of −105.9% in fiscal 2025. It ended the year with $21.8 million of debt and $17.1 million in cash and short-term investments, net debt of $4.7 million. The share count fell 13.6% from 19.2M to 16.6M over 5 years.
See the ADGM income statement, the ADGM chart for price history, or the ADGM stock overview for the latest quote and news.
ADGM key metrics FAQ
What is Adagio Medical's return on equity?
Adagio Medical's return on equity (ROE) was −155.3% in fiscal 2025: net income of -$25.1 million on average shareholders' equity of $16.2 million.
What is Adagio Medical's ROIC?
Adagio Medical's return on invested capital was −105.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Adagio Medical have?
Adagio Medical had total debt of $21.8 million at the end of fiscal 2025, a debt-to-equity ratio of 1.75.
What is Adagio Medical's free cash flow yield?
Adagio Medical generated -$19.4 million of free cash flow in fiscal 2025, a free cash flow yield of −112.5% on its market value at year-end ($17.2 million).
What is Adagio Medical's current ratio?
Adagio Medical's current ratio was 2.44 at the end of fiscal 2025: current assets were 2.44 times current liabilities.